ReviewComputational and structural biotechnology journal2023
Multi-omics in Crohn's disease: New insights from inside.
Review in Computational and structural biotechnology journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Fecal microbiota fermenting simple organic carbon substrates in vitro as microbial factories capable of distinguishing Crohn's disease from healthy states.Microbial cell factories · 2026Article
- Integrated Transcriptomic and Metabolomic Analysis Reveals the Regulatory Mechanisms ofBiology · 2026Article
- Digital twins to accelerate target identification and drug development for immune-mediated disorders.FEBS open bio · 2026Review
- A Developmental Perspective on the Intestinal Microbiota in Crohn's Disease.International journal of molecular sciences · 2026Review
- A cooperative learning framework for the integration of metabolomic data from multiple cohorts and common phenotype identification.Computational and structural biotechnology journal · 2026Article
- Gut Microbiota Modulation by Pomegranate Extract: Insights from a Controlled Supplementation Study.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.International journal of colorectal disease · 2025Review
- Microbiome characterization of patients with Crohn disease and the use of fecal microbiota transplantation: A review.Medicine · 2025Review
- A Knowledge-Guided Large Language Model Framework for Microbiome-Based Disease Diagnosis.Proceedings. IEEE International Conference on Bioinformatics and Biomedicine · 2025Article
- The interaction between gut microbiota and host DNA methylation in the pathogenesis and therapy of inflammatory bowel disease.Frontiers in microbiology · 2025Review
- Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease.Precision clinical medicine · 2024Review
- Interaction between diet and genetics in patients with inflammatory bowel disease.World journal of gastroenterology · 2024Article
- Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate.Biomolecules · 2024Review
- From multi-omics approaches to personalized medicine in myocardial infarction.Frontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with complex clinical manifestations such as chronic diarrhea, weight loss and hematochezia. Despite the increasing incidence worldwide, cure of CD remains extremely difficult. The rapid development of high-throughput sequencing technology with integrated-omics analyses in recent years has provided a new means for exploring the pathogenesis, mining the biomarkers and designing targeted personalized therapeutics of CD. Host genomics and epigenomics unveil heredity-related mechanisms of susceptible individuals, while microbiome and metabolomics map host-microbe interactions in CD patients. Proteomics shows great potential in searching for promising biomarkers. Nonetheless, single omics technology cannot holistically connect the mechanisms with heterogeneity of pathological behavior in CD. The rise of multi-omics analysis integrates genetic/epigenetic profiles with protein/microbial metabolite functionality, providing new hope for comprehensive and in-depth exploration of CD. Herein, we emphasized the different omics features and applications of CD and discussed the current research and limitations of multi-omics in CD. This review will update and deepen our understanding of CD from integration of broad omics spectra and will provide new evidence for targeted individualized therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.